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Abstract
Exacerbations are a major cause of morbidity in asthma and generate high health costs.
Identification and management of adults with asthma who are prone to exacerbations is of
considerable importance as by this means it should be possible to reduce the number of patients
who currently experience inadequately controlled disease. Exacerbations occur most frequently in
individuals with severe disease. Other risk factors include a history of a recent exacerbation, co-
morbidities such as a raised body mass index and psychological problems as well as current smoking
and lower socio-economic status. A low FEV1, particularly if combined with the additional
information from questionnaires helps predict exacerbations. Despite the association between
these risk factors and exacerbations it remains difficult to accurately predict in an individual patient
with asthma whether they will go on to develop an exacerbation in the future. A major aim of
international guidelines on the management of asthma is to prevent future risks of exacerbations,
but some patients, particularly those with severe disease, respond poorly to current therapies and
continue to experience recurrent exacerbations.
There is an unmet need for improved management strategies and drugs targeted at preventing
asthma exacerbations. Monitoring induced sputum eosinophil cell counts is helpful in preventing
exacerbations in some patient with severe asthma. Future developments are likely to include the
identification of better biomarkers to predict exacerbations or the cause of exacerbations,
augmentation of the immunological response to viruses at the time of the exacerbation, the use of
telemonitoring in patients with severe asthma and the development of improved therapies targeted
at reducing exacerbations.
Background
A major goal of international guidelines on the manage-
ment of asthma [1] is to achieve control of current symp-
toms, lung function and reliever inhaler use and to
prevent future risks of exacerbations and decline in lung
function [2]. Despite the widespread dissemination of
asthma guidelines many patients have inadequately con-
trolled disease [3] and experience frequent exacerbations
of asthma [4,5]. Exacerbations are associated with an
accelerated decline in lung function [6], generate high
health costs [7] and are the main cause of mortality in
asthma. The identification and appropriate management
of adults with asthma who are prone to exacerbations is of
considerable importance as by this means it should be
possible to reduce the large number of patients who cur-
rently experience uncontrolled disease.
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Definition and risk factors for exacerbations
Severe exacerbations, defined as the need for courses of
high dose corticosteroids or hospitalization because of
asthma, occur most commonly in patients with severe
asthma. This group can experience exacerbation rates
ranging from 1.5 [8] to over 4 exacerbations per year [4].
Information on previous asthma control, co-morbidities
and demographic factors as well as physiological and
inflammatory biomarkers may help identify some indi-
viduals prone to exacerbations. These factors are often
associated with severe asthma. A history of a recent exac-
erbation within the last 3 months is associated with a con-
siderably increased risk of a future exacerbation [relative
risk (RR) 3.7] [9]. Several co-morbidities in patients with
difficult-to-treat asthma are associated with recurrent
exacerbations including severe nasal sinus disease
[adjusted odds ratio (OR) 3.7], gastro-esophageal reflux
(OR 4.9), recurrent respiratory infections (OR 6.9), psy-
chological problems (OR 10.8) and obstructive sleep
apnea (OR 3.4) [10]. Current smokers with asthma are
more likely to experience exacerbations compared to non-
smokers with asthma [11]. A raised body mass index is
also a risk factor for exacerbations [RR 1.7 (1.2–2.3)] [9]
and hospitalization because of asthma [12]. Hospital
admission rates for asthma in the US are associated with
lower socio-economic status and are higher in black and
Hispanic patients with asthma compared to whites [13]. A
low pre-bronchodilator FEV1 of 60 to 80% of predicted
gives a 2.4-fold increased risk of an exacerbation, which
rises to 4.6-fold increased risk when the pre-bronchodila-
tor FEV1 is < 60% of predicted [14]. Addition of informa-
tion gained from questionnaires, including a history of
pet ownership, increases the likelihood of identifying
exacerbations over the next 30 months to a medium risk
(RR 3.0) or high risk (RR 11) [14].
The categorisation of patients with severe asthma by clus-
ter analyses into different phenotypes termed early onset
atopic asthma, obese non-eosinophilic asthma, early
symptoms predominant asthma and inflammation pre-
dominant asthma found that exacerbation rates were high
in each of the distinct categories, but that no sub-group
was more prone to exacerbations [4]. Thus despite the
association between known risk factors and exacerbations
it remains difficult to accurately predict in an individual
patient with asthma whether they will go on to develop an
exacerbation in the future.
Management of patients prone to exacerbations
Several pharmacological and non-pharmacological man-
agement approaches are likely to be effective in prevent-
ing exacerbations. Current drugs therapies for asthma,
particularly inhaled corticosteroids alone or in combina-
tion with long-acting beta2 agonists, but also leukotriene
modifiers and omalizumab all reduce the rate of asthma
exacerbations [1]. Different ways of using currently avail-
able medication may reduce exacerbation rates. The
SMART approach, which involves using both budesonide
and formoterol given as needed, reduces the frequency of
severe exacerbations in patients receiving regular combi-
nation therapy [15], although the value of this approach
in patients with severe asthma is less clear. The heteroge-
neity of the therapeutic response to corticosteroids and to
other drug therapies for asthma means that some patients
respond poorly to current treatments and continue to
experience recurrent exacerbations [5], probably due to a
combination of genetic and environmental factors [16] as
well as poor adherence to drug therapy. Written individu-
alized management plans, when combined with regular
review, improve asthma control including reduced hospi-
talization and attendance at emergency rooms for exacer-
bations [17].
The effect of treating co-morbidities associated with severe
asthma, targeting smokers with asthma to quit smoking
[18] or patients with a high BMI to lose weight [19], may
result in improvements in indices of current asthma con-
trol. Future studies are needed to assess whether these
interventions reduce exacerbation rates. Avoidance of trig-
ger factors such as allergens, non-steroidal anti-inflamma-
tory agents or occupational agents in sensitive individuals,
as well as exposure to environmental irritants such as pas-
sive smoke, is likely to prevent some exacerbations [1].
Can we do better?
Taken together, there is considerable evidence to indicate
a need for improved methods both to identify adults with
asthma who are prone to exacerbations and also to iden-
tify the early development and cause of an exacerbation.
There is also a need for better management strategies and
drugs targeted at treating and preventing exacerbations.
Monitoring biomarkers of airway inflammation may have
a role in reducing exacerbation rates in selected patients.
Treatment based on serial sputum eosinophil count meas-
urements, prevents exacerbations in patients with severe
asthma [20,21]. Serial exhaled nitric oxide measurements
however, does not decrease exacerbation rates in 12–20
year olds [22] or in adults followed up for one year [23].
In future, it may be possible to use genetic markers to
identify exacerbators. For example, in children and young
adults with asthma the risk of asthma exacerbations is
associated with filagrin null mutations [24] and IL-10 pol-
ymorphisms [25]. The complex and fluctuating interac-
tion between environmental, immunological and
mechanical factors on the risk of future exacerbations may
require the use of sophisticated analytical methods to
assess risk [26]. The majority of asthma exacerbations are
caused by respiratory rhinovirus infections [27]. RecentBMC Pulmonary Medicine 2008, 8:27 http://www.biomedcentral.com/1471-2466/8/27
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studies have demonstrated that patients with asthma are
more susceptible to the clinical and inflammatory adverse
effects of respiratory viruses due to augmented Th2 or
impaired Th1 or IL-10 immunity [28]. These findings sug-
gest that one approach in the future to the management of
exacerbation may be through immunological augmenta-
tion with interferons at the time of the exacerbation [27]
or by the use of specific anti-viral therapies. Telemonitor-
ing of patients with severe asthma may be an advance that
could identify worsening asthma control at an earlier
stage, but evidence for this is still awaited. In the future,
biological therapies, such as anti-IL13, current drugs, such
as macrolides, or novel treatments, such as bronchial ther-
moplasty [29] may prove useful approaches in reducing
exacerbations in some patients with severe asthma. Hope-
fully future research in asthma exacerbations will translate
into improved levels of asthma control within the popu-
lation.
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